Filing summary
Entity and period: The supplied filing is Sevion Therapeutics, Inc.’s Form 10-K for the fiscal year ended June 30, 2017, filed October 13, 2017. It is not identified in the filing as an Eloxx Pharmaceuticals, Inc. 10-K or as a calendar fourth-quarter report; the company and period in the request metadata do not match the filing.
Business context
Sevion was a development-stage biotechnology company pursuing antibody discovery and therapeutic candidates for cancer and immunological diseases. Its lead candidate, SVN001, targets the Kv1.3 ion channel and was in preclinical development. The company had reduced antibody research spending because of limited capital. It reported four employees and four consultants.
Financial performance and position
| Metric | FY ended June 30, 2017 | FY ended June 30, 2016 |
|---|---|---|
| Revenue | $0 | $75,000 |
| Operating expenses | $4.593 million | $11.270 million |
| Operating loss | $4.593 million | $11.195 million |
| Net loss | $5.796 million | $8.268 million |
| Net loss available to common shareholders | $6.194 million | $8.447 million |
| Basic and diluted loss per share | $0.27 | $0.42 |
| Cash used in operating activities | $1.925 million | $3.676 million |
- FY2017 R&D expense was $734,000, down 66.4%; management attributed the reduction principally to sharply curtailed research to preserve cash. General and administrative expense was $1.409 million, down 12.3%.
- FY2017 included a $2.6 million impairment of acquired research and development, a $150,000 gain on patent sales, and a $1.04 million income tax benefit. Fair-value movements and financing-related charges also affected results, including a $1.176 million loss from change in note derivative fair value, a $1.418 million anti-dilution stock issuance charge, and a $285,000 warrant-modification charge.
- Cash and cash equivalents were $33,198 at June 30, 2017, versus $811,000 a year earlier. Working capital was a deficit of approximately $2.490 million; total assets were $5.845 million and total liabilities $4.974 million. Accumulated deficit was $121.824 million.
- FY2017 financing activities provided $1.1 million from convertible notes; investing activities provided $47,500, including $50,000 proceeds from patent sales, partly offset by equipment purchases. No revenue was generated in FY2017.
- At year-end, current notes payable were $407,122 and a $1.845 million derivative liability was recorded. The company had issued $1.1 million of convertible notes during the year; some principal and interest had converted to common stock by June 30. Notes bore 5% or 6% interest and included conversion features. The filing’s subsequent-event note reports that a July 2017 financing triggered mandatory conversion of most notes, with the remaining $250,000 principal plus accrued interest due to convert upon merger consummation.
Changes, outlook, and material risks
- Loss narrowed year over year, and operating cash use declined, but revenue fell to zero and cash fell to a critically low level. Lower expenses largely reflected reduced activity rather than demonstrated operating improvement. FY2017 acquired-R&D impairment increased from $1.7 million in FY2016 to $2.6 million; the prior year also included a $5.781 million goodwill impairment.
- The independent auditor included a going-concern explanatory paragraph. Management said available cash, including the $1.5 million received from OPKO on July 28, 2017, was expected to fund operations through December 31, 2017. The filing says that without further financing or completion of the transaction, Sevion did not expect to have enough cash to continue as a going concern past that date.
- Sevion agreed to acquire Eloxx Pharmaceuticals Ltd. in a merger, subject to closing conditions, including Eloxx shareholder approval and separate financings providing at least $12 million each to Sevion’s business and Eloxx. The transaction was required to close by December 31, 2017 if completed. The $1.5 million OPKO investment counted toward Sevion’s financing condition and was not conditional on closing; other financing raised to satisfy the condition would not be retained if the transaction failed.
- Management anticipated increased R&D spending if it raised capital or completed a strategic transaction, but reported no assurance that financing or the merger would succeed or provide sufficient funds. If financing failed, the company identified alternatives including licensing assets, seeking alliances or a sale, curtailing programs, ceasing operations, or bankruptcy.
- Other significant risks include clinical and regulatory failure, reliance on external research partners, patent and intellectual-property uncertainty, competition, dilution, limited stock trading liquidity, and dependence on future capital. The company disclosed a material weakness in internal control over financial reporting involving accounting and calculations for equity-linked instruments and convertible notes; management concluded controls were ineffective as of June 30, 2017.
- Sevion’s shares traded on OTCQB. The filing reported a FY2017 quarterly bid range of $0.08 to $0.38 and warned of potential dilution from convertible securities, warrants, options, and future financing.
Investor facts to verify
- Confirm the filing relates to Sevion Therapeutics and FY2017, not Eloxx Pharmaceuticals or “2016 Q4.”
- Verify the status and final terms of the proposed Eloxx merger, including whether the financing conditions and shareholder approval were satisfied by the deadline.
- Reconcile post-year-end financing, note conversions, preferred-stock exchanges, and the resulting share count and dilution.
- Assess cash runway and funding needs against the filing’s stated December 31, 2017 operating horizon and going-concern warning.
- Review the impairment assumptions for acquired R&D, the derivative-liability valuation, the unusual noncash charges, and progress in remediating the disclosed material weakness.